Primary Membranous Nephropathy
Top Cited Papers
Open Access
- 26 May 2017
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 12 (6) , 983-997
Abstract
Membranous nephropathy (MN) is a unique glomerular lesion that is the most common cause of idiopathic nephrotic syndrome in nondiabetic white adults. About 80% of cases are renal limited (primary MN, PMN) and 20% are associated with other systemic diseases or exposures (secondary MN). This review focuses only on PMN. Most cases of PMN have circulating IgG4 autoantibody to the podocyte membrane antigen PLA2R (70%), biopsy evidence PLA2R staining indicating recent immunologic disease activity despite negative serum antibody levels (15%), or serum anti-THSD7A (3%–5%). The remaining 10% without demonstrable anti-PLA2R/THSd7A antibody or antigen likely have PMN probably secondary to a different, still unidentified, anti-podocyte antibody. Considerable clinical and experimental data now suggests these antibodies are pathogenic. Clinically, 80% of patients with PMN present with nephrotic syndrome and 20% with non-nephrotic proteinuria. Untreated, about one third undergo spontaneous remission, especially those with absent or low anti-PLA2R levels, one-third progress to ESRD over 10 years, and the remainder develop nonprogressive CKD. Proteinuria can persist for months after circulating anti-PLA2R/THSD7A antibody is no longer detectable (immunologic remission). All patients with PMN should be treated with supportive care from the time of diagnosis to minimize protein excretion. Patients with elevated anti-PLA2R/THSD7A levels and proteinuria >3.5 g/d at diagnosis, and those who fail to reduce proteinuria to <3.5 g after 6 months of supportive care or have complications of nephrotic syndrome, should be considered for immunosuppressive therapy. Accepted regimens include steroids/cyclophosphamide, calcineurin inhibitors, and B cell depletion. With proper management, only 10% or less will develop ESRD over the subsequent 10 years.Keywords
This publication has 91 references indexed in Scilit:
- Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trialThe Lancet, 2013
- Anti-Phospholipase A2 Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2011
- Membranous nephropathy: recent travels and new roads aheadKidney International, 2010
- Spontaneous Remission of Nephrotic Syndrome in Idiopathic Membranous NephropathyJournal of the American Society of Nephrology, 2010
- Alkylating agents in membranous nephropathy: efficacy proven beyond doubtNephrology Dialysis Transplantation, 2010
- The Natural History of the Non-Nephrotic Membranous Nephropathy PatientClinical Journal of the American Society of Nephrology, 2009
- M-Type Phospholipase A2Receptor as Target Antigen in Idiopathic Membranous NephropathyNew England Journal of Medicine, 2009
- A Randomized Pilot Trial Comparing Methylprednisolone Plus a Cytotoxic Agent Versus Synthetic Adrenocorticotropic Hormone in Idiopathic Membranous NephropathyAmerican Journal of Kidney Diseases, 2006
- Pathomechanisms and molecular basis of membranous glomerulopathyThe Lancet, 2004
- Clusterin in renal tissue: preferential localization with the terminal complement complex and immunoglobulin deposits in glomeruliClinical and Experimental Immunology, 1992